Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America.
PLoS One. 2010 Apr 1;5(4):e9987. doi: 10.1371/journal.pone.0009987.
Widely accessible small animal models suitable for the study of hepatitis C virus (HCV) in vivo are lacking, primarily because rodent hepatocytes cannot be productively infected and because human hepatocytes are not easily engrafted in immunodeficient mice.
METHODOLOGY/PRINCIPAL FINDINGS: We report here on a novel approach for human hepatocyte engraftment that involves subcutaneous implantation of primary human fetal hepatoblasts (HFH) within a vascularized rat collagen type I/human fibronectin (rCI/hFN) gel containing Bcl-2-transduced human umbilical vein endothelial cells (Bcl-2-HUVEC) in severe combined immunodeficient X beige (SCID/bg) mice. Maturing hepatic epithelial cells in HFH/Bcl-2-HUVEC co-implants displayed endocytotic activity at the basolateral surface, canalicular microvilli and apical tight junctions between adjacent cells assessed by transmission electron microscopy. Some primary HFH, but not Huh-7.5 hepatoma cells, appeared to differentiate towards a cholangiocyte lineage within the gels, based on histological appearance and cytokeratin 7 (CK7) mRNA and protein expression. Levels of human albumin and hepatic nuclear factor 4alpha (HNF4alpha) mRNA expression in gel implants and plasma human albumin levels in mice engrafted with HFH and Bcl-2-HUVEC were somewhat enhanced by including murine liver-like basement membrane (mLBM) components and/or hepatocyte growth factor (HGF)-HUVEC within the gel matrix. Following ex vivo viral adsorption, both HFH/Bcl-2-HUVEC and Huh-7.5/Bcl-2-HUVEC co-implants sustained HCV Jc1 infection for at least 2 weeks in vivo, based on qRT-PCR and immunoelectron microscopic (IEM) analyses of gel tissue.
CONCLUSION/SIGNIFICANCE: The system described here thus provides the basis for a simple and robust small animal model of HFH engraftment that is applicable to the study of HCV infections in vivo.
目前缺乏适合在体内研究丙型肝炎病毒 (HCV) 的小型动物模型,这主要是因为啮齿动物肝细胞不能被有效地感染,而且人源肝细胞不易在免疫缺陷小鼠中移植。
方法/主要发现:我们在此报告了一种新的人源肝细胞移植方法,该方法涉及将原代人胎肝细胞 (HFH) 植入含有转染了 Bcl-2 的人脐静脉内皮细胞 (Bcl-2-HUVEC) 的血管化大鼠 I 型胶原/人纤维连接蛋白 (rCI/hFN) 凝胶中,该凝胶植入严重联合免疫缺陷 X beige (SCID/bg) 小鼠的皮下。通过透射电子显微镜观察,在 HFH/Bcl-2-HUVEC 共植入物中成熟的肝上皮细胞在基底外侧表面、胆小管微绒毛和相邻细胞之间的顶端紧密连接处显示出内吞作用。一些原代 HFH,但不是 Huh-7.5 肝癌细胞,似乎在凝胶中分化为胆管细胞谱系,基于组织学外观和细胞角蛋白 7 (CK7) mRNA 和蛋白表达。在凝胶植入物中的人白蛋白和肝核因子 4alpha (HNF4alpha) mRNA 表达水平以及植入 HFH 和 Bcl-2-HUVEC 的小鼠血浆中人白蛋白水平,通过在凝胶基质中包含鼠类肝样基底膜 (mLBM) 成分和/或肝细胞生长因子 (HGF)-HUVEC 而有所提高。在体外病毒吸附后,HFH/Bcl-2-HUVEC 和 Huh-7.5/Bcl-2-HUVEC 共植入物在体内至少持续 2 周维持 HCV Jc1 感染,这基于凝胶组织的 qRT-PCR 和免疫电子显微镜 (IEM) 分析。
结论/意义:因此,这里描述的系统为 HFH 移植的简单而强大的小型动物模型提供了基础,该模型适用于体内 HCV 感染的研究。